Novo Nordisk A/S (NYSE:NVO) Upgraded to “Buy” at UBS Group

Novo Nordisk A/S (NYSE:NVO) was upgraded by equities researchers at UBS Group from a “sell” rating to a “buy” rating in a report issued on Wednesday,Benzinga reports.

Other research analysts have also issued research reports about the stock. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Up 2.2 %

Shares of Novo Nordisk A/S stock traded up $1.80 during trading hours on Wednesday, hitting $85.14. The company’s stock had a trading volume of 1,163,677 shares, compared to its average volume of 5,890,926. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market capitalization of $382.07 billion, a PE ratio of 27.55, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The stock has a 50 day moving average of $101.94 and a 200 day moving average of $120.27.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in NVO. Rhumbline Advisers lifted its stake in Novo Nordisk A/S by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 60,974 shares of the company’s stock valued at $8,703,000 after purchasing an additional 270 shares during the last quarter. Gryphon Financial Partners LLC raised its stake in Novo Nordisk A/S by 56.6% in the 2nd quarter. Gryphon Financial Partners LLC now owns 3,086 shares of the company’s stock valued at $440,000 after acquiring an additional 1,116 shares during the period. Headlands Technologies LLC increased its holdings in shares of Novo Nordisk A/S by 33.5% in the second quarter. Headlands Technologies LLC now owns 22,323 shares of the company’s stock valued at $3,186,000 after purchasing an additional 5,607 shares during the last quarter. MGO One Seven LLC lifted its stake in shares of Novo Nordisk A/S by 22.4% during the 2nd quarter. MGO One Seven LLC now owns 19,799 shares of the company’s stock worth $2,826,000 after buying an additional 3,629 shares during the last quarter. Finally, SP Asset Management LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $321,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.